Methotrexate, Doxorubicin, and Cisplatin Versus Methotrexate, Doxorubicin, and Cisplatin + Ifosfamide in Poor Responders to Preoperative Chemotherapy for Newly Diagnosed High-Grade Osteosarcoma (JCOG0905): A Multicenter, Open-Label, Randomized Trial

Hiroaki Hiraga, Toshifumi Ozaki(Okayama University), Junya Toguchida(Kyoto University), Yukihide Iwamoto(Kyushu Rosai Hospital), Toshiyuki Kunisada(Okayama University Hospital), Toshihiro Akisue(Kobe University), Akihito Nagano(Gifu University), Kazuhiro Tanaka(Oita University), Makoto Emori, Kunihiro Asanuma(Mie University), Satoshi Tsukushi(Aichi Cancer Center), Haruhiko Fukuda(National Cancer Center Hospital East), Yoshihiro Nishida(Nagoya University), Hiroyuki Kawashima(Niigata University Medical and Dental Hospital), Masanobu Takeyama(Yokohama City University Hospital), Akira Kawai(NTT (Japan)), Makoto Endo(Kyushu University), Kazuo Isu(Hokkaido University Hospital), Katsutada Hiraoka(Kurume University Hospital), Toru Hiruma, Tsukasa Yonemoto, Tomoko Kataoka(Japan Clinical Cancer Research Organization), Hideki Nishimura(Nagano Municipal Hospital), Robert Nakayama(Keio University), Ryunosuke Machida(Japan Clinical Cancer Research Organization), Taisuke Furuta(Hiroshima University), Shinichirou Yoshida(Tohoku University), Keisuke Ae(The Cancer Institute Hospital), Takeshi Morii(Kyorin University), Hiroshi Hatano(Niigata Cancer Center Hospital)
Journal of Clinical Oncology
March 26, 2025
Cited by 11


Related Papers